adenine has been researched along with Infections, Lentivirus in 4 studies
Excerpt | Relevance | Reference |
---|---|---|
" Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application." | 5.39 | Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. ( Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS, 2013) |
" Variables that can be experimentally manipulated to address specific questions relevant to postexposure prophylaxis (PEP) include timing of initiation of treatment, duration of treatment, dosing regimen, virus strain, and virus inoculum." | 2.40 | Animal studies of prophylaxis. ( Black, RJ, 1997) |
" Intermittently dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigtailed macaques depending on the timing of viral challenge relative to gel application." | 1.39 | Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. ( Dinh, CT; Hendry, RM; Herold, BC; Kiser, PF; Martin, A; McNicholl, JM; Mesquita, PM; Nagaraja, U; Rastogi, R; Smith, JM; Srinivasan, P; Teller, RS, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Smith, JM | 2 |
Rastogi, R | 1 |
Teller, RS | 1 |
Srinivasan, P | 2 |
Mesquita, PM | 1 |
Nagaraja, U | 1 |
McNicholl, JM | 2 |
Hendry, RM | 1 |
Dinh, CT | 1 |
Martin, A | 1 |
Herold, BC | 2 |
Kiser, PF | 1 |
Dinh, C | 1 |
Zhang, J | 1 |
Pau, CP | 1 |
Lo, Y | 1 |
Teller, R | 1 |
Kiser, P | 1 |
Black, RJ | 1 |
Igarashi, T | 1 |
Brown, CR | 1 |
Endo, Y | 1 |
Buckler-White, A | 1 |
Plishka, R | 1 |
Bischofberger, N | 1 |
Hirsch, V | 1 |
Martin, MA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring[NCT02006264] | Phase 1 | 30 participants (Actual) | Interventional | 2013-11-19 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product (NCT02006264)
Timeframe: 14 days of vaginal ring use
Intervention | Adverse events (Number) |
---|---|
TDF Intravaginal Ring | 7 |
Placebo Intravaginal Ring | 1 |
Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period (NCT02006264)
Timeframe: 14 days of vaginal ring use
Intervention | Adverse events (Number) |
---|---|
TDF Intravaginal Ring | 2 |
Placebo Intravaginal Ring | 0 |
TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
Intervention | ng/mg (Median) |
---|---|
TDF Intravaginal Ring | 5.4 |
TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: before and after 14 days of vaginal ring use
Intervention | fmol/mg (Median) |
---|---|
TDF Intravaginal Ring | 120 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
Intervention | ng/mL (Median) | ||||
---|---|---|---|---|---|
C-max CVF VAG TDF | C-max CVF ECX TDF | C-max CVF VAG TFV | C-max CVF ECX TFV | C-max Plasma TFV | |
TDF Intravaginal Ring | 240000 | 210000 | 91000 | 85000 | 1.9 |
TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
Intervention | h (Median) | ||||
---|---|---|---|---|---|
T-max CVF VAG TDF | T-max CVF ECX TDF | T-max CVF VAG TFV | T-max CVF ECX TFV | T-max Plasma TFV | |
TDF Intravaginal Ring | 6 | 5 | 14 | 7 | 14 |
TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects. (NCT02006264)
Timeframe: 1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal
Intervention | ngxd/mL (Median) | ||||
---|---|---|---|---|---|
AUC0-14 (days 0-14), CVF VAG TDF | AUC0-14 (days 0-14), CVF ECX TDF | AUC0-14 (days 0-14), CVF VAG TFV | AUC0-14 (days 0-14), CVF ECX TFV | AUC0-14 (days 0-14), Plasma TFV | |
TDF Intravaginal Ring | 2000000 | 1300000 | 1100000 | 970000 | 9.4 |
1 review available for adenine and Infections, Lentivirus
Article | Year |
---|---|
Animal studies of prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Administration Schedule; Interferon- | 1997 |
3 other studies available for adenine and Infections, Lentivirus
Article | Year |
---|---|
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.
Topics: Adenine; Administration, Intravaginal; Animals; Delayed-Action Preparations; Drug Delivery Systems; | 2013 |
Pharmacokinetic evaluation of tenofovir disoproxil fumarate released from an intravaginal ring in pigtailed macaques after 6 months of continuous use.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV; | 2014 |
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progress | 2001 |